Showing 1681-1690 of 2050 results for "".
- SpyGlass Pharma Unveils 6-Month Data from the First-In-Human Trial of its Drug Delivery Platform for Chronic Eye Conditionshttps://modernod.com/news/spyglass-pharma-unveils-6-month-data-from-the-first-in-human-trial-of-its-drug-delivery-platform-for-chronic-eye-conditions/2481385/SpyGlass Pharma released 6-month data from a first-in-human glaucoma treatment trial showing that its drug delivery platform continues to demonstrate significant IOP lowering in patients with glaucoma or ocular hypertension, according to a company news release. The data were showcased d
- CDC Provides Update on Pseudomonas Aeruginosa Associated with Artificial Tearshttps://modernod.com/news/cdc-provides-update-on-pseudomonas-aeruginosa-associated-with-artificial-tears/2481382/The Centers for Disease Control and Prevention (CDC) issued a Health Alert Network (HAN) Health Advisory in regards to infections of 55 people in 12 states related to the use of artificial tears. Patients with infections reported more than 10 different brands of artifici
- Research Challenges “Sugar Hypothesis” of Diabetic Cataract Developmenthttps://modernod.com/news/research-challenges-sugar-hypothesis-of-diabetic-cataract-development/2481371/New findings from investigators at Brigham and Women’s Hospital, a founding member of the Mass General Brigham health care system, contradict previous notions about sugar’s role i
- TFS HealthScience Acquires Appletree CI Group, Expanding Presence in Ophthalmologyhttps://modernod.com/news/tfs-healthscience-acquires-appletree-ci-group-expanding-into-ophthalmology/2481363/Contract research organization TFS HealthScience announced it has acquired Appletree CI Group, a CRO and global regulatory affairs service provider. Terms of the deal were not disclosed. The deal enhances TFS HealthScience's presence in the fields of op
- Amber Ophthalmics Announces Positive Topline Phase 2 Data Evaluating Nexagon for the Treatment of Persistent Corneal Epithelial Defect (PCED)https://modernod.com/news/amber-ophthalmics-announces-positive-topline-phase-2-data-evaluating-nexagon-for-the-treatment-of-persistent-corneal-epithelial-defect-pced/2481332/Amber Ophthalmics announced positive topline results from the phase 2 randomized, double-masked, vehicle-controlled clinical trial (EXPEDE) evaluating two topically administered concentrations of Nexagon (lufepirsen ophthalmic gel) for the treatment of persistent corneal epithelial defect (P
- Alcon Introduces Reusable Toric Lens with Launch of TOTAL30 for Astigmatismhttps://modernod.com/news/alcon-introduces-reusable-toric-lens-with-launch-of-total30-for-astigmatism/2481324/Alcon announced plans to launch TOTAL30 for Astigmatism, which the company calls the first-and-only reusable contact lens with water gradient material for astigmatic contact lens wearers. Using Alcon’s proprietary water gradient material, first introduced with DAILIES TOTAL1&
- EyePoint Pharmaceuticals Promotes Jay S. Duker, MD, to President and Chief Operating Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-promotes-jay-s-duker-md-to-president-and-chief-operating-officer/2481320/EyePoint Pharmaceuticals announced that Jay S. Duker, MD, who has served as the company’s Chief Operating Officer (COO) since November 2021, has been promoted to the additional role of President. In addition to continuing to oversee his duties as COO, in his expanded role, Dr. Duker wi
- iSTAR Medical Expands Commercial Rollout of MINIject with First Surgeries in Sweden and Norwayhttps://modernod.com/news/istar-medical-expands-commercial-rollout-of-miniject-with-first-surgeries-in-sweden-and-norway/2481272/iSTAR Medical announced that the commercial rollout expansion for MINIject has continued with the first implantations performed in Sweden and Norway. MINIject is iSTAR Medical’s minimally-invasive glaucoma surgery (MIGS) implant and is currently the only commerciall
- Oculis Announces Publication of Positive Phase 2 Data Investigating Topical Anti-TNFα Agent Licaminlimab (OCS-02) in Acute Anterior Uveitishttps://modernod.com/news/oculis-announces-publication-of-positive-phase-2-data-investigating-topical-anti-tnfa-agent-licaminlimab-ocs-02-in-acute-anterior-uveitis/2481255/Oculis announced that the results of an active-controlled, multicenter, randomized, parallel-group phase 2 clinical trial assessing the effect of topical licaminlimab (OCS-02) on anterior chamber (AC) cell grade in patients with acute anterior uveitis (AAU) (NCT02482129) has been publis
- MediPrint Ophthalmics Announces It Has Initiated Its SIGHT-2 Phase 2b Clinical Study for Its Lead Assethttps://modernod.com/news/mediprint-ophthalmics-announces-it-has-initiated-its-sight-2-phase-2b-clinical-study-for-its-lead-asset/2481231/MediPrint Ophthalmics announced it has initiated its SIGHT-2 dose-finding phase 2b study for its proprietary drug-eluting contact lens for glaucoma. This is the second study in its SIGHT (Sustained Innovative Glaucoma and ocular Hypertension Treatment) clinical program aimed at treating